参芪扶正联合PG方案治疗晚期非小细胞肺癌的疗效观察  

Efficacy of Shenqifuzheng injection combined PG therapy in treatment of non-small cell lung cancer

作　　者：黄爱霞[1,2] 姚国相[1,2] 陈燕[1,2] 钱伟[1,2] 浦柳美 鲁立文[1,2] 

机构地区：[1]上海交通大学附属第六人民医院南院 [2]奉贤区中心医院呼吸科,上海201406

出　　处：《中国生化药物杂志》2014年第1期88-89,92,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的观察参芪扶正注射液联合吉西他滨和顺铂(gemcitabine&cisplatin,PG)方案治疗非小细胞肺癌(non—small ceil lung cancer,NSCLC)的疗效。方法选择201 1年8月~201 3年8月在上海交通大学附属第六人民医院南院就诊的NSCLC 76例患者,随机分为观察组和对照组,每组38例。对照组予以吉西他滨和顺铂治疗,观察组在对照组的基础上予以参芪扶正注射液治疗。观察2组治疗后的总有效率、疾病控制率、生活质量和不良反应发生率。结果观察组的总有效率为47.37%,对照组的总有效率为42.11%,2组的总有效率差异无统计学意义,而观察组的疾病控制率为81.58%明显高于对照组的57.89%,差异有统计学意义(X^2=3.990,P<0.05)。观察组的生活质量改善率为60.53%明显优于对照组的31.58%,两组差异有统计学意义(X^245.296,P<0.05)。观察组的白细胞(X^2=4.491,P<0.05)和血小板(X^2=4.491,P<0.05)减少发生率明显低于对照组,而两组的肝功能损害和胃肠道反应差别无统计学意义。结论参芪扶正注射液有助于提高PG方案治疗NSCLC的疗效,并对化疗药物的毒副作用具有一定的缓解作用。Objective To observe the shenqifuzheng injection (SFI) combined with PG therapy (gemcitabine and cisplatin) in patients with non-small cell lung cancer (NSCLC). Method 76 patients with NSCLC were selected from August 2011 to August 2013 and randomly divided into observation group and control group. Each group had 38 cases. The control group received gemcitabine and cisplatin, observation group were gave SFI on the basis of control group. The total efficiency, disease control rate, quality of life and incidence of adverse reactions were observed after treatment in each group. Results The total effective rate was 47.37%in observation group , 42.11%in control group, there was no significant difference between two groups. The disease control rate in observation group was 81.58%higher than 57.89%in control group, the difference was statistically significant (χ2=3.990, P<0.05). The improvement rate in quality of life was 60.53%in observation group better than 31.58%in the control group , the difference was statistically significant (χ2=5.296, P<0.05).The decrease incidence of white blood cell (χ2=4.491, P<0.05) and platelets (χ2=4.491, P<0.05) in observation group were significantly lower compared with the control group, while, there were no difference of liver damage and gastrointestinal reactions between two groups. Conclusion SFI is helpful to improve the efficacy of PG therapy in patients with NSCLC and relieve the side effects of chemotherapy.

关 键 词：参芪扶正注射液 吉西他滨 顺铂 非小细胞肺癌 化疗 

分 类 号：R563[医药卫生—呼吸系统]